Cargando…
Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc
The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by replicating selected results from a substantial number of high-profile papers in the field of cancer biology published between 2010 and 2012. This Registered report describes...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
eLife Sciences Publications, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480271/ https://www.ncbi.nlm.nih.gov/pubmed/26111384 http://dx.doi.org/10.7554/eLife.07072 |
_version_ | 1782378130848088064 |
---|---|
author | Kandela, Irawati Jin, Hyun Yong Owen, Katherine |
author_facet | Kandela, Irawati Jin, Hyun Yong Owen, Katherine |
author_sort | Kandela, Irawati |
collection | PubMed |
description | The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by replicating selected results from a substantial number of high-profile papers in the field of cancer biology published between 2010 and 2012. This Registered report describes the proposed replication plan of key experiments from ‘BET bromodomain inhibition as a therapeutic strategy to target c-Myc’ by Delmore and colleagues, published in Cell in 2011 (Delmore et al., 2011). The key experiments that will be replicated are those reported in Figures 3B and 7C-E. Delmore and colleagues demonstrated that treatment with JQ1, a small molecular inhibitor targeting BET bromodomains, resulted in the transcriptional down-regulation of the c-Myc oncogene in vitro (Figure 3B; Delmore et al., 2011). To assess the therapeutic efficacy of JQ1 in vivo, mice bearing multiple myeloma (MM) lesions were treated with JQ1 before evaluation for tumor burden and overall survival. JQ1 treatment significantly reduced disease burden and increased survival time (Figure 7C-E; Delmore et al., 2011). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange and the results of the replications will be published in eLife. DOI: http://dx.doi.org/10.7554/eLife.07072.001 |
format | Online Article Text |
id | pubmed-4480271 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | eLife Sciences Publications, Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-44802712015-06-26 Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc Kandela, Irawati Jin, Hyun Yong Owen, Katherine eLife Human Biology and Medicine The Reproducibility Project: Cancer Biology seeks to address growing concerns about reproducibility in scientific research by replicating selected results from a substantial number of high-profile papers in the field of cancer biology published between 2010 and 2012. This Registered report describes the proposed replication plan of key experiments from ‘BET bromodomain inhibition as a therapeutic strategy to target c-Myc’ by Delmore and colleagues, published in Cell in 2011 (Delmore et al., 2011). The key experiments that will be replicated are those reported in Figures 3B and 7C-E. Delmore and colleagues demonstrated that treatment with JQ1, a small molecular inhibitor targeting BET bromodomains, resulted in the transcriptional down-regulation of the c-Myc oncogene in vitro (Figure 3B; Delmore et al., 2011). To assess the therapeutic efficacy of JQ1 in vivo, mice bearing multiple myeloma (MM) lesions were treated with JQ1 before evaluation for tumor burden and overall survival. JQ1 treatment significantly reduced disease burden and increased survival time (Figure 7C-E; Delmore et al., 2011). The Reproducibility Project: Cancer Biology is a collaboration between the Center for Open Science and Science Exchange and the results of the replications will be published in eLife. DOI: http://dx.doi.org/10.7554/eLife.07072.001 eLife Sciences Publications, Ltd 2015-06-25 /pmc/articles/PMC4480271/ /pubmed/26111384 http://dx.doi.org/10.7554/eLife.07072 Text en © 2015, Kandela et al http://creativecommons.org/licenses/by/4.0/ This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited. |
spellingShingle | Human Biology and Medicine Kandela, Irawati Jin, Hyun Yong Owen, Katherine Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc |
title | Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc |
title_full | Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc |
title_fullStr | Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc |
title_full_unstemmed | Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc |
title_short | Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc |
title_sort | registered report: bet bromodomain inhibition as a therapeutic strategy to target c-myc |
topic | Human Biology and Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4480271/ https://www.ncbi.nlm.nih.gov/pubmed/26111384 http://dx.doi.org/10.7554/eLife.07072 |
work_keys_str_mv | AT kandelairawati registeredreportbetbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT jinhyunyong registeredreportbetbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT owenkatherine registeredreportbetbromodomaininhibitionasatherapeuticstrategytotargetcmyc AT registeredreportbetbromodomaininhibitionasatherapeuticstrategytotargetcmyc |